Cami Samuels joined Venrock in 2014 and focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Unity Biotechnology (UBX) and as an observer at Corvidia, and recently stepped off the board of REGENXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade where she led investments in Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among many others. She was also a board observer at several companies including Genomic Health (GHDX), Fluidigm (FLDM), and Syrrx (acquired by Takeda). Before Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen). Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.